Evidence map›Paper›PMID 20552377›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2011

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.

Sven Simons, Susanne Ringsdorf, Michael Braun, Ulrich J Mey, Peter F Schwindt, Yon D Ko, Ingo Schmidt-Wolf, Walther Kuhn, Ulrich Jaehde

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 7 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Reviewing cancer care team effectiveness.Journal of oncology practice · 2015
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Implications for medication safety and adherence in dermato-oncology: The AMBORA care program for oral antitumor therapeutics.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Exploring the factors influencing adherence to oral anticancer drugs in patients with digestive cancer: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sven SimonsDepartment of Clinical Pharmacy, Institute of Pharmacy, An der Immenburg 4, 53121, Bonn, Germany.
Susanne Ringsdorf
Michael Braun
Ulrich J Mey
Peter F Schwindt
Yon D Ko
Ingo Schmidt-Wolf
Walther Kuhn
Ulrich Jaehde
University Hospital Bonn · DEJohanniter-Krankenhaus Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn this prospective multi-centre observational cohort study, we investigated the effect of an intensified multidisciplinary pharmaceutical care programme on the adherence of cancer patients treated with capecitabine, a prodrug of fluorouracil. PATIENTS AND

methodsTwenty-four colorectal and 24 breast cancer patients participated in this study. Patients of the control group (n = 24) received standard care, patients of the intervention group (n = 24) received intensified pharmaceutical care consisting of written and spoken information. Adherence to capecitabine chemotherapy was measured using an electronic medication event monitoring system (MEMS™).

resultsPatients in the intervention group exhibited an enhanced but not significantly different mean overall adherence compared to the control group (97.9% vs 90.5%, p = 0.069). Mean daily adherence was significantly higher in the intervention group (96.8% vs 87.2%, p = 0.029). Variability of both adherence parameters was considerably reduced when pharmaceutical care was provided. At the end of the observation period of 126 days, the probability of still being treated with capecitabine was found to be 48% in the control group and 83% in the intervention group (p = 0.019, log-rank test). The relative risk for a deviating drug intake interval, i.e. <10 or >14 instead of 12 h, in the intervention group was found to be 0.51 (95% CI, 0.46-0.56) compared with the control group (p < 0.05, Chi-square test).

conclusionsThe provision of intensified pharmaceutical care can enhance adherence to and prolong treatment with capecitabine. The results underline the importance of multidisciplinary care to assure the effectiveness of oral chemotherapy.

Indexed as

Drug MonitoringPatient Care TeamAntimetabolites, AntineoplasticBreast NeoplasmsCapecitabineColorectal NeoplasmsConfidence IntervalsDeoxycytidineFemaleFluorouracilGermanyHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedStatistics as TopicAntimetabolites, AntineoplasticCapecitabineDeoxycytidineFluorouracil

Identifiers

PMID20552377
PMCPMC3109264
OpenAlexW2034072525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.